- AI-designed ADHD drug sparked fresh investor interest in Bio Protocol’s BIO.
- Increase in volume indicates strong buying.
- The momentum for the token remains strong, but depends on sustained buying pressure.
Bio Protocol’s native token $BIO surged significantly today. This rally has been fueled by the fresh hype around the project’s AI-powered push into decentralized science (DeSci). According to a post on social media platform X, a recent feature on Bankless and a viral X post from the page itself highlighted breakthroughs in AI-driven peptide drug discovery, which increased the buying pressure.
AI Agent Designs ADHD Peptide in 24-hours For Under $1,500
The Bio Protocol’s CEO revealed that their team had created a new ADHD drug candidate in just 24 hours by using AI. Their AI system, PeptAI, not only designed the drug but it also tested it through various simulations and flagged real issues. Moreover, it also estimated that the first lab test would cost just $500-600.
Full early validation could cost around $1,000-$1,500. Usually, pharma companies spend millions on research and it takes years to reach this stage.
How AI is Changing Drug Discovery
This incident is a great example which shows how AI is transforming not just the traditional finance industry but also the research industry. Previously, the biggest barrier was known to be funding. Research only moved forward if it was in line with commercial interests, and hence at times, it would leave many important ideas unexplored.
DeSci (decentralized science) tried to solve this with community funding, but high discovery costs held it back. Now, AI is reducing those costs significantly.
DeSci and Community Funding Power
With lower costs, even a DAO treasury can fund a drug candidate until real lab data is available. This opens doors for studying diseases that pharma companies usually ignore. For example, ADHD research around the orexin system has existed for years but was never commercially pursued, until now.
Bio Protocol sits at the centre of this change because it provides a platform that is combining community funding with “agentic science,” where AI systems act like researchers. Its tools, like BIOS, help with research and analysis, while the platform routes funds to specialized research DAOs.
The Challenges That Still Exist
Even though there has been great progress, three major hurdles still remain. First, key drug data is locked within pharma companies. Projects like Molecule aim to create open research hubs to solve this. Second, physical lab testing is still necessary and takes time. Third, clinical trials on humans remain expensive and follow traditional systems.
Strong Buying Shows Real Interest
BIO’s recent price jump was not random, but rather it was backed by massive trading activity. Trading volume surged by 146%, reaching approximately $180 million, while the price rose around 10%. This kind of move usually signals strong buyer confidence, not just a short-term spike.
A healthy turnover ratio of 2.64 also shows there’s enough liquidity, meaning large trades can happen without major price swings.
What stands out more is that BIO moved independently of the broader crypto market and Bitcoin. While the overall crypto market slowed down, BIO kept on increasing. This suggests strong, project-specific demand, possibly from large investors betting on the DeSci trend.
At press time, the price of the BIO token stands at $0.0317 with an uptick of 7.0% in the last 24-hours as per CoinGecko.
Key Levels to Watch
As of now, BIO needs to hold on to $0.03 level as support. If it drops below, then the price of the token could fall toward the $0.028 mark due to profit taking. On the other side, the next target for the token is $0.035. If it breaks this level with a huge volume, then it can easily push toward $0.04.
Also Read: TRON’s TRX Price Drops Despite Bullish Treasury & Integration News
